A descriptive study of racial inequalities in mortality from hepatocellular cancer before and after licensure of lifesaving drugs for hepatitis C virus in the United States

BACKGROUND: Since 1979, mortality from hepatocellular cancer (HCC) has doubled in the United States (US). Lifesaving drugs, prohibitively expensive for some, were approved and marketed to treat hepatitis C virus (HCV), a major risk factor for HCC, beginning in 1997. After the prior introduction of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Robert S, Mejia, Maria C, Salemi, Jason L, Gonzalez, Sandra J, Aliyu, Muktar H, Husaini, Baqar A, Zoorob, Roger J, Hennekens, Charles H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200781/
https://www.ncbi.nlm.nih.gov/pubmed/32382721
http://dx.doi.org/10.1016/j.eclinm.2020.100350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200781/
https://www.ncbi.nlm.nih.gov/pubmed/32382721
http://dx.doi.org/10.1016/j.eclinm.2020.100350

Ejemplares similares